Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining bryostatin 1 with interleukin-2 may cause a stronger immune response and kill
more tumor cells. Randomized phase II trial to study the effectiveness of combining
interleukin-2 and bryostatin 1 in treating patients who have advanced kidney cancer